Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
By H. Kantarjian, Y. Oki, G. Garcia-Manero, Xuelin Huang, S. O'brien, J. Cortes, S. Faderl, C. Bueso-Ramos, F. Ravandi, Z. Estrov and 7 more. Blood, 2007
718 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/76fdc9bad073557b03bf8d1acf11cc3c776bd024
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
- Jean-Pierre Issa
- S. Baylin
- F. Lyko
- Carlo Stresemann
- Peter A. Jones
- Peter W. Laird
- Manel Esteller
- Keith D. Robertson
Citations in the corpus
- Transient Low Doses of DNA Demethylating Agents Exert Durable Anti-tumor Effects on Hematological and Epithelial Tumor Cells (2012, background): “Remarkably, the improved clinical efficacy and safety profile have emerged only as doses of the drugs, given either alone (Issa et al., 2004; Kantarjian et al., 2006, 2007) or in combination with histone deacetylase (HDAC) inhibitors (Gore et al., 2006), were significantly reduced.”
- Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. (2012, background): “In a randomized study of three decitabine regimens in patients with MDS or chronic myelomonocytic leukemia, intravenous (IV) decitabine 20 mg/m(2) per day infused over 1 hour for 5 days optimally induced hypomethylation and provided the best complete remission (CR) rates.(11) This regimen demonstrat”
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine (2008, background): “In this context, it is interesting to notice that clinical decitabine administration schedules with relatively high dose intensity have shown better response rates than schedules that continuously maintain low plasma drug levels.(32) Thus, downstream effects of demethylation might also be important ”
- Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. (2013, methodology): “The 5-day intravenous schedule with the highest dose-intensity, was selected as optimal.(195) For personal use only.”